This page shows the latest bevacizumab news and features for those working in and with pharma, biotech and healthcare.
The US Food and Drug Administration (FDA) has approved Taiho Oncology’s Lonsurf (trifluridine and tipiracil) with bevacizumab for use in adults with heavily pre-treated metastatic colorectal cancer (mCRC). ... He added: "Notably, the use of Lonsurf
The analysis of IMbrave050 showed that Tecentriq in combination with Avastin (bevacizumab) significantly improved recurrence-free survival (RFS) in HCC patients with an increased risk of recurrence following resection or ablation
Despite not being approved for wet AMD, Roche’s Avastin (bevacizumab) had been shown in independent trials to be effective in treating the condition and, as the cancer drug is significantly
The pre-specified interim analysis of the IMbrave050 study showed that Tecentriq in combination with Avastin (bevacizumab) significantly improved RFS in HCC patients with an increased risk of recurrence following resection
of FRα and who had been treated with one to three prior systemic treatment regimens – at least one of which included Avastin (bevacizumab).
Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) has been approved by the European Commission (EC) for the treatment of multiple types of cancer, the company announced. ... Vegzelma is a recombinant humanised monoclonal antibody
More from news
Approximately 21 fully matching, plus 197 partially matching documents found.
Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo
Roche instituted similar principles in the promotion of its cancer drug, Avastin (bevacizumab), which works by finding and blocking the blood supply feeding malignant tumors.
Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I
NA. Bevacizumab. Biocad. Russia. BCD-021. Clinical. NSCLC: Ph III started in Oct 2012.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
According to their study, Black patients were significantly less likely than white patients to show short-term visual improvement after being given bevacizumab (Avastin), a common treatment used in the
These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
No results were found
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...